The Union Health Ministry has amended national drug regulations to require a doctor's prescription for the sale of cough syrups across India [1].

This regulatory shift aims to curb the uncontrolled distribution of cough formulations and mitigate risks associated with contaminated medicines. By removing these products from over-the-counter availability, the government intends to strengthen monitoring, and improve overall safety standards for patients [1, 4].

The government achieved this change by amending the Drugs Rules, which were originally enacted in 1945 [2]. Specifically, the ministry removed cough syrups from Schedule K, the list of drugs that can be sold without a prescription [2, 3].

Under the previous regulatory framework, certain exemptions allowed for the sale of these medications in rural areas. Specifically, the previous rules permitted sales in villages with fewer than 1,000 residents without requiring a retail drug licence [2]. The new amendment eliminates these loopholes to ensure a uniform standard of oversight across both urban and rural settings [1, 3].

Officials said the move is necessary to address contamination concerns that have affected drug safety [4]. By mandating a prescription, the health ministry can better track the distribution of these syrups, and ensure they are administered under professional medical supervision [3, 4].

The transition to a prescription-only model represents a significant tightening of the Drugs and Cosmetics Act's application to common respiratory medications [2]. This change affects pharmacies nationwide, requiring them to verify medical authorization before dispensing these specific formulations [1, 3].

“The Union Health Ministry has amended national drug regulations to require a doctor's prescription for the sale of cough syrups across India.”

This policy shift reflects a broader effort by the Indian government to align its pharmaceutical regulations with global safety standards. By removing the rural exemption and the Schedule K status, India is prioritizing patient safety and traceability over ease of access, likely in response to previous international and domestic concerns regarding contaminated cough syrup exports and domestic misuse.